Sale!

DCAF17 Gene Hypogonadism Alopecia Diabetes Mellitus Mental Retardation and Extrapyramidal Syndrome Genetic Test Cost

Original price was: 5,600 د.إ.Current price is: 4,400 د.إ.

-21%

The “DCAF17 Gene Hypogonadism Alopecia Diabetes Mellitus Mental Retardation and Extrapyramidal Syndrome Genetic Test” is a comprehensive diagnostic tool offered by DNA Labs UAE, designed to identify mutations in the DCAF17 gene. This gene is implicated in a rare, autosomal recessive disorder characterized by a constellation of symptoms including hypogonadism (a condition where the sex glands produce few or no hormones), alopecia (hair loss), diabetes mellitus (a group of diseases that result in too much sugar in the blood), mental retardation, and extrapyramidal syndrome (a neurological syndrome associated with decreased or abnormal movements).

Given the complex nature of the disorder and the wide range of symptoms it encompasses, accurate diagnosis is crucial for effective management and treatment. The test targets individuals who present symptoms of the aforementioned conditions, or those with a family history of the disorder, providing them with crucial insights into their genetic makeup.

DNA Labs UAE, a leading provider of genetic testing services in the region, offers this test at a cost of 4400 AED. The test is conducted in a state-of-the-art laboratory setting, ensuring high-quality, reliable results. By identifying mutations in the DCAF17 gene, the test plays a vital role in the diagnosis and understanding of this rare condition, paving the way for targeted treatment strategies and genetic counseling for affected individuals and their families.

Home  Sample collection service available

  • 100% accuaret Test Results
  • Ranked as Most trusted Genetic DNA Lab
  • This test is not intended for medical diagnosis or treatment
Guaranteed Safe Checkout

DCAF17 Gene Hypogonadism Alopecia Diabetes Mellitus Mental Retardation and Extrapyramidal Syndrome Genetic Test

Genetic testing plays a crucial role in diagnosing and managing various genetic disorders. One such disorder is Woodhouse-Sakati syndrome (WSS), which is associated with the DCAF17 gene. This syndrome is characterized by a combination of symptoms including hypogonadism, alopecia, diabetes mellitus, mental retardation, and extrapyramidal syndrome.

The DCAF17 gene is analyzed through Next-Generation Sequencing (NGS) genetic testing. This advanced technology allows for the simultaneous analysis of multiple genes, making it a powerful tool for diagnosing genetic disorders. By performing NGS genetic testing on individuals suspected to have WSS, healthcare professionals can identify any mutations or variants in the DCAF17 gene that may be causing the symptoms.

Before undergoing the DCAF17 gene test, it is important to provide a clinical history of the patient. Additionally, a genetic counseling session may be conducted to draw a pedigree chart of family members affected by DCAF17 Gene Hypogonadism, alopecia, Diabetes mellitus, mental retardation, and extrapyramidal syndrome. This helps in understanding the inheritance pattern and the likelihood of passing on the disorder to future generations.

The test can be conducted using blood or extracted DNA, or even a single drop of blood on an FTA card. The cost of the DCAF17 Gene Hypogonadism, alopecia, Diabetes mellitus, mental retardation, and extrapyramidal syndrome Genetic Test is AED 4400.0. The test report is typically delivered within 3 to 4 weeks.

It is crucial to note that genetic testing should always be performed and interpreted by qualified healthcare professionals, especially those specializing in genetics. They can provide appropriate counseling and guidance based on the test results, ensuring the best possible care for the individual.

Genetic testing for DCAF17 Gene Hypogonadism, alopecia, Diabetes mellitus, mental retardation, and extrapyramidal syndrome is an essential step towards accurate diagnosis and effective management of this rare genetic disorder. By understanding the genetic basis of the disorder, healthcare professionals can develop personalized treatment plans and provide support to affected individuals and their families.

Test Name DCAF17 Gene Hypogonadism alopecia Diabetes mellitus mental retardation and extrapyramidal syndrome Genetic Test
Components
Price 4400.0 AED
Sample Condition Blood or Extracted DNA or One drop Blood on FTA Card
Report Delivery 3 to 4 Weeks
Method NGS Technology
Test type Dysmorphology
Doctor Pediatrics
Test Department: Genetics
Pre Test Information Clinical History of Patient who is going for DCAF17 Gene Hypogonadism, alopecia, Diabetes mellitus, mental retardation and extrapyramidal syndrome NGS Genetic DNA Test. A Genetic Counselling session to draw a pedigree chart of family members affected with DCAF17 Gene Hypogonadism, alopecia, Diabetes mellitus, mental retardation and extrapyramidal syndrome NGS Genetic DNA Test gene DCAF17
Test Details

DCAF17 gene is associated with a rare genetic disorder known as Woodhouse-Sakati syndrome (WSS). This syndrome is characterized by a combination of symptoms including hypogonadism (underdeveloped or non-functioning reproductive organs), alopecia (hair loss), diabetes mellitus (high blood sugar levels), mental retardation (intellectual disability), and extrapyramidal syndrome (movement disorders).

NGS (Next-Generation Sequencing) genetic testing can be used to analyze the DCAF17 gene and identify any mutations or variants that may be present. This type of testing allows for the simultaneous analysis of multiple genes, making it a powerful tool for diagnosing genetic disorders.

By performing NGS genetic testing on an individual suspected to have WSS, healthcare professionals can identify any mutations in the DCAF17 gene that may be causing the symptoms. This can help confirm the diagnosis and provide valuable information for managing the condition.

It’s important to note that genetic testing should always be performed and interpreted by qualified healthcare professionals who specialize in genetics. They can provide appropriate counseling and guidance based on the test results to ensure the best possible care for the individual.